Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL8587449 | 0.96 | CPA1 (0.52) | CPA1ALDH1A1TSHR | |
| SCHEMBL11875036 | 0.84 | CPA1 (0.44) | CPA1ALDH1A1TSHR | |
| SCHEMBL5467078 | 0.79 | ALDH1A1 (0.41) | CPA1ALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL3789231 | 0.77 | CPA1 (0.52) | CPA1ALDH1A1TSHR | |
| SCHEMBL6578335 | 0.76 | CPA1 (0.37) | CPA1ALDH1A1KDM4EMAPT | |
| SCHEMBL8587453 | 0.76 | CPA1 (0.38) | CPA1ALDH1A1 | |
| SCHEMBL18463625 | 0.75 | CPA1 (0.54) | CPA1TSHR | |
| SCHEMBL5356077 | 0.75 | — | — | |
| SCHEMBL6927866 | 0.74 | — | — | |
| SCHEMBL9115533 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS (UK) LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| CN-102112436-A | Novel and efficient method for synthesis of amino acid | GENERICS UK LTD | 2011-06-29 | — | — | CN | claimed |
| EP-2280930-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | Generics [UK] Limited (GB) | 2011-02-09 | — | — | EP | claimed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| WO-2009087650-A2 | A NOVEL PROCESS FOR SYNTHESIS OF PREGABALIN FROM SUBSTITUTED CYCLOPROPANE INTERMEDIATE AND A PROCESS FOR ENZYMATIC RESOLUTION OF RACEMIC PREGABALIN | V.B. MEDICARE PVT. LTD. (IN) | 2009-07-16 | — | — | WO | claimed |
| EP-3154930-B1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-9745249-B2 | Method for the preparation of beta-substituted gamma-amino carboxylic acids | SIEGFRIED LTD. (CH) | 2017-08-29 | — | — | US | disclosed |
| US-20170114003-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD. (CH) | 2017-04-27 | — | — | US | disclosed |
| EP-3154930-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | Siegfried Ltd. (CH) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189068-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD. (CH) | 2015-12-17 | — | — | WO | disclosed |
| US-20110245508-A1 | Processes For Making Pregabalin And Intermediates Therefor | THIJS LAMBERTUS | 2011-10-06 | — | — | US | disclosed |
| US-20110245508-A1 | Processes For Making Pregabalin And Intermediates Therefor | THIJS LAMBERTUS | 2011-10-06 | — | — | US | disclosed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009087650-A3 | A NOVEL PROCESS FOR SYNTHESIS OF PREGABALIN FROM SUBSTITUTED CYCLOPROPANE INTERMEDIATE AND A PROCESS FOR ENZYMATIC RESOLUTION OF RACEMIC PREGABALIN | V.B. MEDICARE PVT. LTD. (IN) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009087650-A2 | A NOVEL PROCESS FOR SYNTHESIS OF PREGABALIN FROM SUBSTITUTED CYCLOPROPANE INTERMEDIATE AND A PROCESS FOR ENZYMATIC RESOLUTION OF RACEMIC PREGABALIN | V.B. MEDICARE PVT. LTD. (IN) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087650-A2 | A NOVEL PROCESS FOR SYNTHESIS OF PREGABALIN FROM SUBSTITUTED CYCLOPROPANE INTERMEDIATE AND A PROCESS FOR ENZYMATIC RESOLUTION OF RACEMIC PREGABALIN | V.B. MEDICARE PVT. LTD. (IN) | 2009-07-16 | — | — | WO | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GLUL, GRIK5, GABRE | CPA1 2592/4885ALDH1A1 1509/4885TSHR 3771/4885 |
| US-20170114003-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | GLUL, GABRB2, GABRB1 | CPA1 2759/4885ALDH1A1 513/4885TSHR 4275/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CPA1 1654/4885ALDH1A1 515/4885TSHR 2407/4885 |
| US-20110245508-A1 | Processes For Making Pregabalin And Intermediates Therefor | GABRB2, GABRB1, GABRB3 | CPA1 3552/4885ALDH1A1 510/4885TSHR 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.